Seitaro Terakura

Seitaro Terakura

Auto-generated profile, based on publicly available information

Seitaro Terakura

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KWKeisuke Watanabe
Keisuke Watanabe
STSeitaro Terakura
Seitaro Terakura
AMAnton C. Martens
Anton C. Martens
TMTom van Meerten
Tom van Meerten
SUSusumu Uchiyama
Susumu Uchiyama
MMMakoto Murata
Makoto Murata
The effectiveness of chimeric Ag receptor (CAR)–transduced T (CAR-T) cells has been attributed to supraphysiological signaling through CARs. Second- and later-generation CARs simultaneously transmit costimulatory signals with CD3ζ signals upon ligation, but may lead to severe adverse effects owing to the recognition of minimal Ag expression outside the target tumor. Currently, the threshold target Ag density for CAR-T cell lysis and further activation, including cytokine production, has not yet been investigated in detail. Therefore, we determined the threshold target Ag density required to induce CAR-T cell responses using novel anti-CD20 CAR-T cells with a CD28 intracellular domain and a CD20-transduced CEM cell model. The newly developed CD20CAR–T cells demonstrated Ag-specific lysis and cytokine secretion, which was a reasonable level as a second-generation CAR. For lytic activity, the threshold Ag density was determined to be ∼200 molecules per target cell, whereas the Ag density required for cytokine production of CAR-T cells was ∼10-fold higher, at a few thousand per target cell. CD20CAR–T cells responded efficiently to CD20-downregulated lymphoma and leukemia targets, including rituximab- or ofatumumab-refractory primary chronic lymphocytic leukemia cells. Despite the potential influence of the structure, localization, and binding affinity of the CAR/Ag, the threshold determined may be used for target Ag selection. An Ag density below the threshold may not result in adverse effects, whereas that above the threshold may be sufficient for practical effectiveness. CD20CAR–T cells also demonstrated significant lytic activity against CD20-downregulated tumor cells and may exhibit effectiveness for CD20-positive lymphoid malignancies.

5 January 2012 in Blood
Verified
Journal Article
Open access
PDF file
STSeitaro Terakura
Seitaro Terakura
TYTori N. Yamamoto
Tori N. Yamamoto
RGRebecca A. Gardner
Rebecca A. Gardner
CTCameron J. Turtle
Cameron J. Turtle
MJMichael C. Jensen
Michael C. Jensen
SRStanley R. Riddell
Stanley R. Riddell
The adoptive transfer of donor T cells that have been genetically modified to recognize leukemia could prevent or treat leukemia relapse after allogeneic HSCT (allo-HSCT). However, adoptive therapy after allo-HSCT should be performed with T cells that have a defined endogenous TCR specificity to avoid GVHD. Ideally, T cells selected for genetic modification would also have the capacity to persist in vivo to ensure leukemia eradication. Here, we provide a strategy for deriving virus-specific T cells from CD45RA−CD62L+CD8+ central memory T (TCM) cells purified from donor blood with clinical grade reagents, and redirect their specificity to the B-cell lineage marker CD19 through lentiviral transfer of a gene encoding a CD19-chimeric Ag receptor (CAR). Virus-specific TCM were selectively transduced by exposure to the CD19 CAR lentivirus after peptide stimulation, and bi-specific cells were subsequently enriched to high purity using MHC streptamers. Activation of bi-specific T cells through the CAR or the virus-specific TCR elicited phosphorylation of downstream signaling molecules with similar kinetics, and induced comparable cytokine secretion, proliferation, and lytic activity. These studies identify a strategy for tumor-specific therapy with CAR-modified T cells after allo-HSCT, and for comparative studies of CAR and TCR signaling.

31 July 2016 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
RSReona Sakemura
Reona Sakemura
STSeitaro Terakura
Seitaro Terakura
KWKeisuke Watanabe
Keisuke Watanabe
JJJakrawadee Julamanee
Jakrawadee Julamanee
ETErina Takagi
Erina Takagi
HKHitoshi Kiyoi
Hitoshi Kiyoi
T cells genetically modified with a CD19 chimeric antigen receptor (CD19CAR) are remarkably effective against B-cell malignancies in clinical trials. However, major concerns remain regarding toxicities, such as hypogammaglobulinemia, due to B-cell aplasia or severe cytokine release syndrome after overactivation of CAR T cells. To resolve these adverse events, we aimed to develop an inducible CAR system by using a tetracycline regulation system that would be activated only in the presence of doxycycline (Dox). In this study, the second-generation CD19CAR was fused into the third-generation Tet-On vector (Tet-CD19CAR) and was retrovirally transduced into primary CD8+ T cells. Tet-CD19CAR T cells were successfully generated and had minimal background CD19CAR expression without Dox. Tet-CD19CAR T cells in the presence of Dox were equivalently cytotoxic against CD19+ cell lines and had equivalent cytokine production and proliferation upon CD19 stimulation, compared with conventional CD19CAR T cells. The Dox(+) Tet-CD19CAR T cells also had significant antitumor activity in a xenograft model. However, without Dox, Tet-CD19CAR T cells lost CAR expression and CAR T-cell functions in vitro and in vivo, clearly segregating the “On” and “Off” status of Tet-CD19CAR cells by Dox administration. In addition to suicide-gene technology, controlling the expression and the functions of CAR with an inducible vector is a potential solution for CAR T-cell therapy–related toxicities, and may improve the safety profile of CAR T-cell therapy. This strategy might also open the way to treat other malignancies in combination with other CAR or TCR gene–modified T cells. Cancer Immunol Res; 4(8); 1–11. ©2016 AACR.

6 November 2017 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NHNaoki Hosen
Naoki Hosen
YMYukiko Matsunaga
Yukiko Matsunaga
KHKana Hasegawa
Kana Hasegawa
HMHiroshi Matsuno
Hiroshi Matsuno
YNYuki Nakamura
Yuki Nakamura
AKAtsushi Kumanogoh
Atsushi Kumanogoh

1 February 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
STSeitaro Terakura
Seitaro Terakura
YAYoshiko Atsuta
Yoshiko Atsuta
NTNobuhiro Tsukada
Nobuhiro Tsukada
TKTakeshi Kobayashi
Takeshi Kobayashi
MTMasatsugu Tanaka
Masatsugu Tanaka
KMKoichi Miyamura
Koichi Miyamura
To investigate an up-to-date alternative donor selection strategy, we compared the transplantation outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation (UBMT) with those of umbilical cord blood transplantation (UCBT) and redefined the role of UCBT with extended analysis. Using Cox and competing risk regression analyses, we analyzed the transplantation outcomes in adult patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). A total of 2472 first myeloablative transplantations between 2000 and 2010 were included (8/8 UBMT, 1001; 7/8 UBMT, 656; UCBT, 815). For acute and chronic graft-versus-host disease (GVHD) and nonrelapse mortality (NRM), we applied the combined analyses including both AML and ALL data. In the multivariate analyses, severe acute GVHD and NRM after UCBT were comparable with 8/8 UBMT, whereas those after 7/8 UBMT were significantly higher. The incidence of extensive chronic GVHD was significantly lower with UCBT compared with after 8/8 and 7/8 UBMT. With adjusted analyses for AML, UCBT and 8/8 UBMT showed similar overall survival (OS), whereas 7/8 UBMT showed inferior OS. For ALL, we found no significant difference in OS among the 3 groups. Cord blood may be the first choice alternative to 8/8 UBMT for both AML and ALL.

12 April 2004 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
TNT Nishida
T Nishida
MHM Hamaguchi
M Hamaguchi
NHN Hirabayashi
N Hirabayashi
MHM Haneda
M Haneda
STS Terakura
S Terakura
YKY Kodera
Y Kodera